17-7674884-A-T
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PM5PP3_Strong
The NM_000546.6(TP53):c.647T>A(p.Val216Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V216G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000546.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Li-Fraumeni syndrome Uncertain:1
This sequence change replaces valine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 216 of the TP53 protein (p.Val216Glu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 376672). Invitae Evidence Modeling incorporating data from in vitro experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is expected to disrupt TP53 function with a positive predictive value of 97.5%. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.V216E variant (also known as c.647T>A), located in coding exon 5 of the TP53 gene, results from a T to A substitution at nucleotide position 647. The valine at codon 216 is replaced by glutamic acid, an amino acid with dissimilar properties. This alteration is located in the DNA-binding domain of p53 and has shown deficient transactivation activity in yeast based functional studies (IARC TP53 databse; Kato S et al. Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8424-9; Concin N et al. Clin. Cancer Res., 2005 Dec;11:8372-83; Gonin-Laurent N et al. Carcinogenesis, 2006 Jun;27:1266-72). Although this specific alteration has not been reported in the literature, another alteration at the same codon (p.V216M) was reported in a child diagnosed with adrenocorticol carcinoma (Bougeard G et al. J. Clin. Oncol., 2015 Jul;33:2345-52). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at